



Laboratory Investigation Report

Miss. CAROLINE NATALIE UTTANGI Name

DOB 20/11/1973

Age / Gender 51 Y / Female Referred by DR.AISHA UMER

CITICARE MEDICAL CENTER Centre

Ref No. Sample No. 2504560054

Collected 07/04/2025 11:15

Registered 08/04/2025 12:20 Reported 08/04/2025 14:18

BIOCHEMISTRY

Flag Unit Result Test **Reference Range** Methodology **C-REACTIVE PROTEIN (CRP)** < 5.0 Particle-enhanced 1 mg/L Please note change.

Source: Roche IFU.

immunoturbidimetric assay

INTERPRETATION NOTES:

- 1. CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- 3. CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- 4. CRP response may be less pronounced in patients suffering from liver disease.
- 5. CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection.

Serum Sample Type:

End of Report

Dr. Vyoma V Shah Dr. Adley Mark Fernandes M.D (Pathology) M.D (Pathology) **Pathologist Clinical Pathologist**

This is an electronically authenticated report

P.O Box: 49527

Page 1 of 3

ACCREDITED

Greeshma P Sidharthan

Printed on: 08/04/2025 15:38

www.biosytech.com





ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under

> Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae





Ref No.

Laboratory Investigation Report

Name : Miss. CAROLINE NATALIE UTTANGI

DOB 20/11/1973 Sample No. 2504560054 Age / Gender 51 Y / Female Collected 07/04/2025 11:15 Referred by DR.AISHA UMER Registered 08/04/2025 12:20 08/04/2025 15:36 Centre CITICARE MEDICAL CENTER Reported

HEMATOLOGY					
Test	Result	Flag	Unit	Reference Range	Methodology
COMPLETE BLOOD COUNT (CBC)					
HEMOGLOBIN	9.2	L	g/dL	12 - 15.5	Photometric
RBC COUNT	4.3		10^6/μL	3.9 - 5	Electrical Impedance
HEMATOCRIT	29.6	L	%	35 - 45	Calculation
MCV	68.1	L	fL	82 - 98	Calculation
МСН	21.2	L	pg	27 - 32	Calculation
мснс	31.2	L	g/dL	32 - 37	Calculation
RDW	18	н	%	11.9 - 15.5	Calculation
RDW-SD	43.3		fL		Calculation
MPV	9.2		fL	7.6 - 10.8	Calculation
PLATELET COUNT	336		10^3/uL	150 - 450	Electrical Impedance
РСТ	0.3		%	0.01 - 9.99	Calculation
PDW	16.3		Not Applicable	0.1 - 99.9	Calculation
NUCLEATED RBC (NRBC)^	0.6		/100 WBC		VCS 360 Technology
ABSOLUTE NRBC COUNT^	0.03		10^3/uL		Calculation
EARLY GRANULOCYTE COUNT (EGC)^	0.2		%		VCS 360 Technology
ABSOLUTE EGC^	0		10^3/uL		Calculation
WBC COUNT	4.8		10^3/μL	4 - 11	Electrical Impedance
DIFFERENTIAL COUNT (DC)					
NEUTROPHILS	68		%	40 - 75	VCS 360 Technology
LYMPHOCYTES	24	L	%	30 - 60	VCS 360 Technology
EOSINOPHILS	3		%	0 - 6	VCS 360 Technology
MONOCYTES	5		%	1 - 6	VCS 360 Technology
BASOPHILS	0		%	0 - 1	VCS 360 Technology
ABSOLUTE COUNT					
ABSOLUTE NEUTROPHIL COUNT	3.2		10^3/uL	1.6 - 8.25	Calculation
ABSOLUTE LYMPHOCYTE COUNT	1.0	L	10^3/uL	1.2 - 6.6	Calculation
ABSOLUTE MONOCYTE COUNT	0.2		10^3/uL	0.04 - 0.66	Calculation
ABSOLUTE EOSINOPHIL COUNT	0.1		10^3/uL	0 - 0.66	Calculation
ABSOLUTE BASOPHIL COUNT	0.0		10^3/uL	0 - 0.11	Calculation

Gome V. Shah

Dr. Adley Mark Fernandes Dr. Vyoma V Shah
M.D (Pathology) M.D (Pathology)
Pathologist Clinical Pathologist

This is an electronically authenticated report

Page 2 of 3

ANJUMOL D V
Laboratory Technologist

Printed on: 08/04/2025 15:38

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com





2504560054

07/04/2025 11:15

08/04/2025 12:20 08/04/2025 15:36

Laboratory Investigation Report

Name Miss. CAROLINE NATALIE UTTANGI

DOB 20/11/1973 Age / Gender 51 Y / Female Referred by DR.AISHA UMER

Centre CITICARE MEDICAL CENTER

Ref No.

Sample No.

Collected

Registered

Reported

HEMATOLOGY

Result Flag Unit **Reference Range** Methodology **Test**


COMPLETE BLOOD COUNT (CBC)

INTERPRETATION NOTES:

Please note update on CBC report format, reference ranges and method(Beckman Coulter).

EDTA Whole Blood Sample Type:

End of Report



Dr. Adley Mark Fernandes M.D (Pathology) **Pathologist**

This is an electronically authenticated report

Dr. Vyoma V Shah M.D (Pathology) **Clinical Pathologist**

Page 3 of 3

ANJUMOL D V

Laboratory Technologist Printed on: 08/04/2025 15:38

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





P.O Box: 49527 Dubai, UAE Tel: +971 4 398 8567 reports@biosytech.ae www.biosytech.com